These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 31151801)

  • 1. Safety, toxicity and immunogenicity of a malaria vaccine based on the circumsporozoite protein (FMP013) with the adjuvant army liposome formulation containing QS21 (ALFQ).
    Cawlfield A; Genito CJ; Beck Z; Bergmann-Leitner ES; Bitzer AA; Soto K; Zou X; Hadiwidjojo SH; Gerbasi RV; Mullins AB; Noe A; Waters NC; Alving CR; Matyas GR; Dutta S
    Vaccine; 2019 Jun; 37(29):3793-3803. PubMed ID: 31151801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013.
    Genito CJ; Beck Z; Phares TW; Kalle F; Limbach KJ; Stefaniak ME; Patterson NB; Bergmann-Leitner ES; Waters NC; Matyas GR; Alving CR; Dutta S
    Vaccine; 2017 Jul; 35(31):3865-3874. PubMed ID: 28596090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of immunogenicity and safety outcomes of a malaria vaccine FMP013/ALFQ in rhesus macaques (Macaca mulatta) of Indian and Chinese origin.
    Martin ML; Bitzer AA; Schrader A; Bergmann-Leitner ES; Soto K; Zou X; Beck Z; Matyas GR; Dutta S
    Malar J; 2019 Nov; 18(1):377. PubMed ID: 31775762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-in-human assessment of safety and immunogenicity of low and high doses of Plasmodium falciparum malaria protein 013 (FMP013) administered intramuscularly with ALFQ adjuvant in healthy malaria-naïve adults.
    Hutter JN; Robben PM; Lee C; Hamer M; Moon JE; Merino K; Zhu L; Galli H; Quinn X; Brown DR; Duncan E; Bolton J; Zou X; Angov E; Lanar DE; Rao M; Matyas GR; Beck Z; Bergmann-Leitner E; Soisson LA; Waters NC; Ngauy V; Regules J; Dutta S
    Vaccine; 2022 Sep; 40(40):5781-5790. PubMed ID: 36055874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of a
    Langowski MD; Khan FA; Bitzer AA; Genito CJ; Schrader AJ; Martin ML; Soto K; Zou X; Hadiwidjojo S; Beck Z; Matyas GR; Livingstone MC; Batchelor AH; Dutta S
    Proc Natl Acad Sci U S A; 2020 Feb; 117(6):3114-3122. PubMed ID: 31988134
    [No Abstract]   [Full Text] [Related]  

  • 6. Preclinical evaluation of the safety and immunogenicity of a vaccine consisting of Plasmodium falciparum liver-stage antigen 1 with adjuvant AS01B administered alone or concurrently with the RTS,S/AS01B vaccine in rhesus primates.
    Pichyangkul S; Kum-Arb U; Yongvanitchit K; Limsalakpetch A; Gettayacamin M; Lanar DE; Ware LA; Stewart VA; Heppner DG; Mettens P; Cohen JD; Ballou WR; Fukuda MM
    Infect Immun; 2008 Jan; 76(1):229-38. PubMed ID: 17954725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone.
    Stewart VA; McGrath SM; Dubois PM; Pau MG; Mettens P; Shott J; Cobb M; Burge JR; Larson D; Ware LA; Demoitie MA; Weverling GJ; Bayat B; Custers JH; Dubois MC; Cohen J; Goudsmit J; Heppner DG
    Infect Immun; 2007 May; 75(5):2283-90. PubMed ID: 17307942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced Immunogenicity and Protective Efficacy of a
    Ramakrishnan A; Schumack NM; Gariepy CL; Eggleston H; Nunez G; Espinoza N; Nieto M; Castillo R; Rojas J; McCoy AJ; Beck Z; Matyas GR; Alving CR; Guerry P; Poly F; Laird RM
    mSphere; 2019 May; 4(3):. PubMed ID: 31043512
    [No Abstract]   [Full Text] [Related]  

  • 9. Heterologous prime-boost immunization in rhesus macaques by two, optimally spaced particle-mediated epidermal deliveries of Plasmodium falciparum circumsporozoite protein-encoding DNA, followed by intramuscular RTS,S/AS02A.
    Walsh DS; Gettayacamin M; Leitner WW; Lyon JA; Stewart VA; Marit G; Pichyangkul S; Gosi P; Tongtawe P; Kester KE; Holland CA; Kolodny N; Cohen J; Voss G; Ballou WR; Heppner DG
    Vaccine; 2006 May; 24(19):4167-78. PubMed ID: 16574282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rhesus macaque and mouse models for down-selecting circumsporozoite protein based malaria vaccines differ significantly in immunogenicity and functional outcomes.
    Phares TW; May AD; Genito CJ; Hoyt NA; Khan FA; Porter MD; DeBot M; Waters NC; Saudan P; Dutta S
    Malar J; 2017 Mar; 16(1):115. PubMed ID: 28288639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial.
    White MT; Verity R; Griffin JT; Asante KP; Owusu-Agyei S; Greenwood B; Drakeley C; Gesase S; Lusingu J; Ansong D; Adjei S; Agbenyega T; Ogutu B; Otieno L; Otieno W; Agnandji ST; Lell B; Kremsner P; Hoffman I; Martinson F; Kamthunzu P; Tinto H; Valea I; Sorgho H; Oneko M; Otieno K; Hamel MJ; Salim N; Mtoro A; Abdulla S; Aide P; Sacarlal J; Aponte JJ; Njuguna P; Marsh K; Bejon P; Riley EM; Ghani AC
    Lancet Infect Dis; 2015 Dec; 15(12):1450-8. PubMed ID: 26342424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant Full-length Plasmodium falciparum Circumsporozoite Protein-Based Vaccine Adjuvanted With Glucopyranosyl Lipid A-Liposome Quillaja saponaria 21: Results of Phase 1 Testing With Malaria Challenge.
    Friedman-Klabanoff DJ; Berry AA; Travassos MA; Shriver M; Cox C; Butts J; Lundeen JS; Strauss KA; Joshi S; Shrestha B; Mo AX; Nomicos EYH; Deye GA; Regules JA; Bergmann-Leitner ES; Pasetti MF; Laurens MB
    J Infect Dis; 2024 Jun; 229(6):1883-1893. PubMed ID: 38330357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of rts,s+trap malaria vaccine, formulated in the as02a adjuvant system, in infant rhesus monkeys.
    Walsh DS; Pichyangkul S; Gettayacamin M; Tongtawe P; Siegrist CA; Hansukjariya P; Kester KE; Holland CA; Voss G; Cohen J; Stewart AV; Miller RS; Ballou WR; Heppner DG
    Am J Trop Med Hyg; 2004 May; 70(5):499-509. PubMed ID: 15155981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A.
    Spring MD; Cummings JF; Ockenhouse CF; Dutta S; Reidler R; Angov E; Bergmann-Leitner E; Stewart VA; Bittner S; Juompan L; Kortepeter MG; Nielsen R; Krzych U; Tierney E; Ware LA; Dowler M; Hermsen CC; Sauerwein RW; de Vlas SJ; Ofori-Anyinam O; Lanar DE; Williams JL; Kester KE; Tucker K; Shi M; Malkin E; Long C; Diggs CL; Soisson L; Dubois MC; Ballou WR; Cohen J; Heppner DG
    PLoS One; 2009; 4(4):e5254. PubMed ID: 19390585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and αDEC-CSP in non human primates.
    Tewari K; Flynn BJ; Boscardin SB; Kastenmueller K; Salazar AM; Anderson CA; Soundarapandian V; Ahumada A; Keler T; Hoffman SL; Nussenzweig MC; Steinman RM; Seder RA
    Vaccine; 2010 Oct; 28(45):7256-66. PubMed ID: 20846528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial.
    Datoo MS; Natama MH; Somé A; Traoré O; Rouamba T; Bellamy D; Yameogo P; Valia D; Tegneri M; Ouedraogo F; Soma R; Sawadogo S; Sorgho F; Derra K; Rouamba E; Orindi B; Ramos Lopez F; Flaxman A; Cappuccini F; Kailath R; Elias S; Mukhopadhyay E; Noe A; Cairns M; Lawrie A; Roberts R; Valéa I; Sorgho H; Williams N; Glenn G; Fries L; Reimer J; Ewer KJ; Shaligram U; Hill AVS; Tinto H
    Lancet; 2021 May; 397(10287):1809-1818. PubMed ID: 33964223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial.
    Asante KP; Abdulla S; Agnandji S; Lyimo J; Vekemans J; Soulanoudjingar S; Owusu R; Shomari M; Leach A; Jongert E; Salim N; Fernandes JF; Dosoo D; Chikawe M; Issifou S; Osei-Kwakye K; Lievens M; Paricek M; Möller T; Apanga S; Mwangoka G; Dubois MC; Madi T; Kwara E; Minja R; Hounkpatin AB; Boahen O; Kayan K; Adjei G; Chandramohan D; Carter T; Vansadia P; Sillman M; Savarese B; Loucq C; Lapierre D; Greenwood B; Cohen J; Kremsner P; Owusu-Agyei S; Tanner M; Lell B
    Lancet Infect Dis; 2011 Oct; 11(10):741-9. PubMed ID: 21782519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Virus-Like Particle Vaccine Encoding the Circumsporozoite Protein of
    Kurtovic L; Wetzel D; Reiling L; Drew DR; Palmer C; Kouskousis B; Hanssen E; Wines BD; Hogarth PM; Suckow M; Jenzelewski V; Piontek M; Chan JA; Beeson JG
    Front Immunol; 2021; 12():641421. PubMed ID: 33815393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Similarities and differences of chemical compositions and physical and functional properties of adjuvant system 01 and army liposome formulation with QS21.
    Alving CR; Rao M; Matyas GR
    Front Immunol; 2023; 14():1102524. PubMed ID: 36761767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Live attenuated rubella vectors expressing Plasmodium falciparum circumsporozoite protein (Pf-CSP) provide a novel malaria vaccine platform in the rhesus macaque.
    Virnik K; Zhou W; Medvedev A; Walsh G; Perry-Anderson J; Majam V; Felber BK; Kumar S; Berkower I
    Biochem Biophys Res Commun; 2021 Nov; 577():58-63. PubMed ID: 34507066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.